SCHEMBL5647895

SCHEMBL5647895

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1-c1cc(F)ccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
ALDH1A1 P00352 7/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
HPGD P15428 4/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 4/20 0.39
ALOX15 P16050 3/20 0.39
HSD17B10 Q99714 3/20 0.39
POLB P06746 1/20 0.38
MDM2 Q00987 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAT2A P31153 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TP53 P04637 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649140 0.92 MAPT (0.47) MAPTALDH1A1LMNATSHRKMT2A
SCHEMBL5653022 0.89 MAPT (0.41) MAPTALDH1A1LMNATSHRKMT2A
SCHEMBL5651315 0.88 MAPT (0.43) MAPTALDH1A1TSHRKMT2AMEN1
SCHEMBL5649662 0.88 MAPT (0.43) MAPTALDH1A1TSHRKMT2AMEN1
SCHEMBL5652325 0.84 MAPT (0.47) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL5654208 0.84 MAPT (0.47) MAPTALDH1A1LMNATSHRKMT2A
SCHEMBL5668234 0.83 TRPM8 (0.48) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL5652293 0.82 MAPT (0.44) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL5651789 0.82 MAPT (0.48) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL5648182 0.81 TRPM8 (0.45) MAPTALDH1A1KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAPT 3795/4885ALDH1A1 1498/4885LMNA 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.